Event 2025

Focal Lines takes the stage at UBC Innovation's 2025 Venture Showcase

Focal Lines Technologies was selected to present at UBC Innovation's 2025 Venture Showcase at UBC Robson Square — pitching alongside leading BC ventures to investors, researchers, and the broader innovation ecosystem.

Read More →
Award March 2024

Focal Lines graduates from Life Sciences BC's 2024 Investor Readiness Program

Focal Lines completed Life Sciences BC's 2024 Investor Readiness Program, mentored by Brenda Irwin, Managing Partner at Relentless Venture Fund. Over six months of coaching, workshops, and peer feedback, Focal Lines became investor-ready.

Read More →
Grant 2024

Health Research BC & Mitacs fund UBC research in partnership with Focal Lines

Health Research BC and Mitacs awarded a grant supporting UBC Biomedical Engineering PhD candidate Fraser Douglas to advance Focal Lines' fabric EMG sensor technology — focusing on electrode shift analysis and high-density muscle mapping to bring clinical-grade monitoring into home rehabilitation settings.

Read More →
Press 2024

Focal Lines featured in Praxis SCI Incubate — In Conversation with Charlie Vu

Praxis Spinal Cord Institute sat down with Managing Director Charlie Vu to discuss Focal Lines' journey through the SCI Validate Program — from validating product-market fit with clinicians and people with lived SCI experience, to building a clear roadmap for regulatory approval and commercialization.

Read More →
Award October 2023

Focal Lines joins Life Sciences BC's 2024 Investor Readiness Program

Life Sciences BC selected Focal Lines Technologies as one of a select group of BC life sciences companies for its 2024 Investor Readiness Program — a six-month mentorship pairing emerging companies with industry entrepreneurs to prepare for investment and growth.

Read More →
Press 2023

Focal Lines selected for Praxis SCI Incubate 2023 Cohort

Praxis Spinal Cord Institute announced Focal Lines Technologies as one of three companies selected worldwide for its SCI Incubate 2023 cohort — chosen by an expert panel of researchers, commercial leaders, and people with lived SCI experience to accelerate early-stage innovation into commercial reality.

Read More →